BRIEF-European Medicines Agency's CHMP recommends approval for Merck's Keytruda

* European Medicines Agency's CHMP recommends approval for Merck's Keytruda® (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.